Pacira BioSciences, Inc. PCRX Royalty revenue — Total net product sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s royalty revenue — total net product sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s royalty revenue — total net product sales?
- Pacira BioSciences, Inc. (PCRX) reported royalty revenue — total net product sales of $0 in Q1 2026.
- How has Pacira BioSciences, Inc.'s royalty revenue — total net product sales changed year-over-year?
- Pacira BioSciences, Inc.'s royalty revenue — total net product sales decreased by 100.0% year-over-year, from $1.33M to $0.
- What is the long-term trend for Pacira BioSciences, Inc.'s royalty revenue — total net product sales?
- Over 4 years (2021 to 2025), Pacira BioSciences, Inc.'s royalty revenue — total net product sales has grown at a 9.9% compound annual growth rate (CAGR), from $2.44M to $3.56M.
- What does royalty revenue — total net product sales mean?
- This metric represents the total net sales generated by products or services associated with the royalty revenue segment. It reflects the underlying commercial performance and market adoption of the assets that drive royalty-based income streams. Investors use this to gauge the direct sales volume and market penetration of the specific portfolio contributing to royalty earnings.